These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37380634)

  • 41. Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study.
    Singh R; Shaheer M; Sobhia ME
    J Biomol Struct Dyn; 2023 Jul; 41(10):4421-4443. PubMed ID: 35574601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Experience with Delamanid in an XDR TB Case - Case Report.
    Mohan N; Kaur M; Singhal L; Saini V; Chander J
    Infect Disord Drug Targets; 2021; 21(4):637-639. PubMed ID: 32691718
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
    J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
    Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE
    Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
    López-Gavín A; Tudó G; Vergara A; Hurtado JC; Gonzalez-Martín J
    Int J Antimicrob Agents; 2015 Nov; 46(5):582-5. PubMed ID: 26421981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
    Aher RB; Sarkar D
    J Biomol Struct Dyn; 2021 Feb; 39(3):889-900. PubMed ID: 31983295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR; Marathe PA
    J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
    Brecik M; Centárová I; Mukherjee R; Kolly GS; Huszár S; Bobovská A; Kilacsková E; Mokošová V; Svetlíková Z; Šarkan M; Neres J; Korduláková J; Cole ST; Mikušová K
    ACS Chem Biol; 2015 Jul; 10(7):1631-6. PubMed ID: 25906160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
    Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
    PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
    Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
    Sgaragli G; Frosini M; Saponara S; Corelli F
    Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.
    Tao X; Gao C; Huang ZG; Luo W; Liu KL; Peng CT; Ding CZ; Li J; Chen SH; Yu LT
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2511-2515. PubMed ID: 31353295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coenzyme F
    Purwantini E; Loganathan U; Mukhopadhyay B
    J Bacteriol; 2018 Dec; 200(23):. PubMed ID: 30249701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maximizing bactericidal activity with combinations of bioreduced drugs.
    Goldman RC
    Future Med Chem; 2010 Aug; 2(8):1253-71. PubMed ID: 21426017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053.
    Chiarelli LR; Salina EG; Mori G; Azhikina T; Riabova O; Lepioshkin A; Grigorov A; Forbak M; Madacki J; Orena BS; Manfredi M; Gosetti F; Buzzi A; Degiacomi G; Sammartino JC; Marengo E; Korduláková J; Riccardi G; Mikušová K; Makarov V; Pasca MR
    ACS Infect Dis; 2020 Feb; 6(2):313-323. PubMed ID: 31729215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.